Pagaya's completion of its first M&A signals ability to accelerate its vision and add talented leadership
Darwin expands Pagaya's SFR platform into a next-generation, fully-integrated offering, optimizing
Gainers
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.